Imanis Life Sciences

Menu

Development and Validation of IMMUNO-COV™: a test measuring SARS-CoV-2-neutralizing antibodies

Imanis helps develop and validate a clinical assay for measuring SARS-CoV-2-neutralizing antibodies

May 28, 2020, Imanis Life Sciences, Rochester MN

Imanis Life Sciences and Vyriad announced today the publication of a scientific paper on the development and validation of IMMUNO-COV™, a high-throughput clinical test to quantitatively measure SARS-CoV-2-neutralizing antibodies, the specific subset of anti-SARS-CoV-2 antibodies that block viral infection. The paper is available on bioRxiv, a free online archive and distribution service for non-peer-reviewed manuscripts in the life sciences.

The paper is titled, “Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.” bioRxiv accepts non-peer-reviewed articles to facilitate the rapid sharing of new scientific information about COVID-19 and other life sciences areas of research.

The disease-causing SARS-CoV-2 virus uses its spike protein to infect healthy cells and spread throughout the body. The IMMUNO-COV antibody test uses an innocuous virus that has been engineered to carry this SARS-CoV-2 spike glycoprotein on its surface. It analyzes human blood serum to detect only the antibodies capable of ‘blocking’ the action of this spike glycoprotein, thus preventing the SARS-CoV-2 virus from infecting new cells. This is distinct from most existing serology tests which do not confirm the virus-neutralizing function of antibodies they detect. News release.

Vyriad and Imanis Life Sciences developed the assay in collaboration with Regeneron and the Mayo Clinic.

Learning Resources

Stay Informed

Stay up to date on the latest from the Imanis team, including product releases, promotional codes, and exciting new advancements in noninvasive in vivo imaging!